Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Susan Mayor
Publikováno v:
BMJ. :i4535
Targeted case finding based on estimating patients’ cardiovascular risk and then inviting those likely to be at high risk for a full assessment increases the number of patients started on antihypertensive and statin treatment for primary prevention
Autor:
Susan M Smith, Tom Fahey
Publikováno v:
BMJ. 348:g4028-g4028
Abramson and colleagues highlight uncertainties about adverse effects of statins for the primary prevention of cardiovascular disease in patients at low absolute cardiovascular risk.1 2 There is a substantial discrepancy between observational studies
Autor:
Peter C Gøtzsche
Publikováno v:
BMJ. 348:g3724-g3724
The 2011 Cochrane review of statins for the primary prevention of cardiovascular disease reported a risk ratio of 1.03 for muscle pain—3% more patients developed muscle pain on the drug than on placebo.1 However, industry funded randomised trials a
Publikováno v:
BMJ. 347:f6123-f6123
A review of statins for primary prevention of cardiovascular disease could alter guidance for those with a 10 year risk of less than 10%. John Abramson and colleagues argue that statins have no overall health benefit in this population and that presc
Autor:
Anne Negård, Torbjørn Wisløff, Bjørn Gjelsvik, Inger Njølstad, Serena Tonstad, Ole Frithjof Norheim, Eivind Meland, Steinar Madsen, Tor Ole Klemsdal, Frøydis Ulvin, Stein Narvesen
Publikováno v:
BMJ. 343:d3626-d3626
Norway decided not to follow European guidelines on preventing cardiovascular disease and instead developed its own with age based thresholds. Ole Norheim and colleagues explain the rationale behind them
Autor:
John P. D. Reckless
Publikováno v:
BMJ. 342:d201-d201
The current model in the UK is not necessarily the right one or the only one Two linked analysis articles (doi:10.1136/bmj.c6244; doi:10.1136/bmj.c6312) and one research study (doi:10.1136/bmj.d108) on aspects of prevention of cardiovascular disease
Publikováno v:
BMJ. 281:597-599
Booklets from several countries on various aspects of cardiovascular disease, intended for distribution to the public and to patients, could be classified into three categories dealing with primary prevention, secondary prevention, and management. Mu